Clinical Scorecard: Infection Risks Linked to Colonization by Multidrug-Resistant Gram-Negative Bacteria: A Comprehensive Review and Meta-Analysis

At a Glance

Key Highlights

• Pooled incidence of infection following colonization is approximately 22% for both ESBL-producing Enterobacterales and carbapenem-resistant Enterobacterales.
• Current decolonization interventions show inconsistent benefit; novel approaches require accurate infection risk data to inform clinical trials.
• Heterogeneity in study populations limits generalizability; high-quality data on mortality and transmission post-colonization are limited.

Guideline-Based Recommendations

Diagnosis

• Use culture-based and molecular methods to detect asymptomatic colonization with MDR-GNB, especially ESBL-E and CRE.

Management

• Recognize colonization as a significant risk factor for subsequent infection; consider this in infection prevention and patient counseling.
• Current decolonization methods lack consistent efficacy; further research into novel decolonization strategies is warranted.

Monitoring & Follow-up

• Monitor colonized patients for development of infection given the substantial risk (~22%).
• Surveillance should include assessment of transmission and mortality outcomes, although data are currently limited.

Risks

• Colonization with MDR-GNB substantially increases risk of infection with limited therapeutic options and higher associated mortality.
• Heterogeneity in patient populations and study designs may affect risk estimates and applicability.

Patient & Prescribing Data

Individuals colonized with multidrug-resistant gram-negative bacteria, notably ESBL-E and CRE carriers.

Infection occurs in approximately 22% of colonized patients; current decolonization treatments have inconsistent benefits, highlighting need for novel therapies.

Clinical Best Practices

• Screen high-risk patients for MDR-GNB colonization using reliable microbiological methods.
• Counsel colonized patients regarding their increased risk of infection and potential outcomes.
• Incorporate colonization status into infection prevention protocols and antimicrobial stewardship programs.
• Support and participate in clinical trials evaluating new decolonization agents informed by accurate infection risk data.

References

• AMSTAR 2 Tool for Quality Assessment
• Open Science Framework Registration Y9D76